Elekta AB (publ) (EKTAF)

Elekta AB (publ) (EKTAF) Healthcare & Pipeline Overview

Elekta AB (publ) is a global medical technology firm based in Stockholm, Sweden, specializing in advanced clinical tools for cancer and neurological conditions. The company provides a comprehensive portfolio including radiotherapy, radiosurgery, brachytherapy, and neurosurgery solutions, serving a critical and growing global healthcare market with innovative treatment technologies.

What Is the Investment Thesis for EKTAF?

Elekta AB (publ) operates within the growing medical technology sector, focusing on cancer and neurological disorder treatments, driven by increasing global demand for advanced care. The company's robust product portfolio, including the Elekta Unity MR-Linac and Leksell Gamma Knife, positions it to capitalize on technological advancements in precision medicine. Despite a current profit margin of -3.1%, reflecting ongoing investments or operational costs, its gross margin of 37.4% indicates strong underlying profitability on its core products and services. With a market capitalization of $1.93B and a beta of 0.95, Elekta exhibits moderate market volatility. Key growth catalysts include the expanding global incidence of cancer, driving demand for its radiotherapy and radiosurgery solutions, and continuous innovation in its product lines, such as the integration of AI and cloud services. The company's established global presence and comprehensive offerings in brachytherapy and neurosurgery further support long-term revenue growth. However, investors should monitor the impact of currency fluctuations on reported earnings and the company's ability to maintain market share amidst competitive pressures.

Based on FMP financials and quantitative analysis

EKTAF Key Highlights

• Market Capitalization: $2.39 billion, reflecting its valuation as a mid-sized medical technology firm.
• Gross Margin: 37.4%, indicating strong profitability on its core product and service sales before operating expenses.
• Profit Margin: -3.1%, suggesting current unprofitability, potentially due to investments or operational costs.
• Dividend Yield: 4.58%, offering a significant return to shareholders despite negative profit margins.
• Beta: 0.95, indicating the stock's volatility is slightly lower than the overall market.

Who Are EKTAF's Competitors?

EKTAF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EKTAF's Key Strengths?

• Comprehensive portfolio of advanced medical technology for cancer and neurological conditions.
• Global presence and established reputation in the medical technology sector since 1972.
• Innovative product offerings like the Elekta Unity MR-Linac and Leksell Gamma Knife series.
• Increasing global demand for cancer treatment solutions.

What Are EKTAF's Weaknesses?

• Currently operating with a negative profit margin of -3.1%.
• Exposure to currency fluctuations due to international operations, impacting reported earnings.
• Reliance on a highly specialized and competitive medical technology market.
• "Unknown" disclosure status for OTC trading, potentially limiting investor information.

What Could Drive EKTAF Stock Higher?

• Increasing global demand for advanced cancer and neurological treatments, driving market for Elekta's solutions.
• Continuous innovation and product development, such as enhancements to the Elekta Unity MR-Linac and Leksell Gamma Knife series.
• Expansion of integrated software and cloud-based solutions, enhancing recurring revenue streams and customer engagement.
• Potential market penetration in underserved regions for advanced radiotherapy and radiosurgery.

What Are the Key Risks for EKTAF?

• Financial-distress signal — its Altman Z-Score of 1.14 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-6.4%) — the business is not currently generating profit on shareholder capital.
• Exposure to currency fluctuations, which can negatively impact reported earnings given its international operations.
• Intense competition within the medical technology sector, requiring continuous innovation to maintain market share.
• Global economic downturns or healthcare spending cuts could reduce demand for capital-intensive medical equipment.
• Regulatory changes or delays in product approvals in key markets, affecting time-to-market and revenue.
• Challenges in maintaining profitability, as indicated by the current negative profit margin.

What Are the Growth Opportunities for EKTAF?

• **Expanding Global Cancer Treatment Demand**: The increasing global incidence of cancer is a primary driver for Elekta's growth. As populations age and lifestyle factors contribute to higher cancer rates worldwide, the demand for advanced and effective treatment modalities like radiotherapy and radiosurgery continues to surge. Elekta's comprehensive suite of linear accelerators, brachytherapy solutions, and Gamma Knife systems directly addresses this expanding market need, providing essential tools for healthcare systems globally to combat the disease. This demographic trend ensures a sustained market for Elekta's core offerings for the foreseeable future, particularly in emerging economies where access to advanced care is improving.
• **Innovation in Radiotherapy Technology**: Elekta's continuous investment in research and development, exemplified by products like the Elekta Unity MR-Linac and Elekta Harmony, represents a significant growth opportunity. The Elekta Unity, which combines an MRI scanner with a linear accelerator, offers real-time imaging during treatment, enhancing precision and potentially improving patient outcomes. Such cutting-edge technologies allow Elekta to maintain a competitive edge and capture market share in the high-value segment of precision radiation oncology. The ongoing evolution of these platforms ensures Elekta remains at the forefront of advanced cancer treatment, attracting leading cancer centers globally.
• **Growth in Brachytherapy Solutions**: Elekta's extensive brachytherapy portfolio, including image-guided systems like Elekta Studio and specialized applicators, presents a distinct growth avenue. Brachytherapy is a highly effective treatment for various cancers, particularly cervical and prostate. As treatment protocols evolve and awareness of brachytherapy's benefits grows, Elekta is well-positioned to expand its market presence. The integration of smart tools like Oncentra Brachy and advanced afterloaders further enhances the efficiency and precision of these treatments, driving adoption among oncology departments seeking comprehensive and adaptable solutions for localized cancer care.
• **Expansion of Neurosurgery Product Line**: The Leksell Gamma Knife series and Leksell Stereotactic Systems offer precise radiosurgery and minimally invasive neurosurgery capabilities, addressing a growing need for non-invasive brain and neurological disorder treatments. As medical understanding of neurological conditions advances and patient preference shifts towards less invasive procedures, the demand for such specialized tools is expected to increase. Elekta's established reputation in this niche, coupled with continuous product enhancements like the Leksell Gamma Knife Lightning, allows it to capture a larger share of the global neurosurgery market, offering high-precision solutions for complex conditions.
• **Development of Integrated Software and Cloud Services**: Elekta's offerings like MOSAIQ Plaza and Elekta Axis Cloud represent a strategic shift towards integrated software and managed hosting services. This provides a recurring revenue stream and enhances customer stickiness by embedding Elekta's solutions deeper into hospital workflows. As healthcare providers increasingly adopt digital transformation and seek efficient, secure, and integrated data management solutions, Elekta's cloud-based platforms and treatment management software become vital. This segment offers significant growth potential by providing value-added services beyond hardware sales, fostering long-term partnerships and expanding the total addressable market.

What Opportunities Does EKTAF Have?

• Growing global incidence of cancer driving demand for radiotherapy and radiosurgery.
• Continued technological advancements in precision medicine and integrated treatment solutions.
• Expansion into emerging markets with increasing healthcare infrastructure investments.
• Further development and adoption of cloud-based treatment management services.

What Threats Does EKTAF Face?

• Intense competition from other major medical device manufacturers.
• Adverse currency fluctuations impacting financial performance.
• Potential global economic downturns affecting healthcare capital expenditure.
• Regulatory changes or delays in product approvals in key markets.

What Are EKTAF's Competitive Advantages?

• **Proprietary Technology**: Development of advanced, specialized systems like the Elekta Unity MR-Linac and Leksell Gamma Knife, which integrate complex imaging and treatment delivery.
• **Established Brand and Reputation**: Over 50 years in the medical technology sector, building trust and a global installed base with healthcare providers.
• **Comprehensive Portfolio**: Offers a wide range of solutions across radiotherapy, radiosurgery, brachytherapy, and neurosurgery, providing integrated care pathways.
• **Regulatory Expertise**: Navigating stringent global medical device regulations requires significant expertise and investment, creating barriers to entry for new competitors.
• **Service and Support Network**: A global network for installation, maintenance, and support, crucial for complex medical equipment, enhancing customer loyalty.

What Does EKTAF Do?

Elekta AB (publ), established in 1972 and headquartered in Stockholm, Sweden, is a global leader in medical technology, dedicated to providing advanced clinical tools for the precise treatment of cancer and neurological disorders. The company's foundational mission has evolved from pioneering radiation therapy to offering a comprehensive suite of integrated solutions across the entire cancer care continuum. Elekta's extensive product portfolio encompasses state-of-the-art radiotherapy systems, such as the Versa HD for complex cases like brain metastases, the groundbreaking Elekta Unity MR-Linac which integrates MRI with a linear accelerator for real-time tumor visualization, and the Elekta Harmony linear accelerator designed for efficiency. Other key radiotherapy systems include Elekta Infinity and Elekta Synergy, which incorporate advanced image guidance capabilities. Beyond hardware, Elekta provides crucial treatment management, quality assurance, and motion management technologies, exemplified by MOSAIQ Plaza for multidisciplinary cancer care and the Elekta Axis Cloud managed hosting service. In brachytherapy, their offerings range from the image-guided Elekta Studio and mobile CT ImagingRing to specialized applicators like Venezia and Geneva for cervical cancer, supported by the Oncentra Brachy smart tool and Flexitron afterloader. For radiosurgery, the renowned Leksell Gamma Knife series—Icon, Perfexion, and Lightning—delivers highly precise and accelerated treatments for various indications. Additionally, Elekta supplies neurosurgery products, including the Leksell Vantage and Leksell Stereotactic Systems, facilitating both intracranial and minimally invasive procedures. This broad and integrated product offering positions Elekta as a critical partner for healthcare providers globally, addressing the increasing demand for advanced cancer and neurological treatments.

What Products and Services Does EKTAF Offer?

• Develops and manufactures advanced medical technology for cancer and neurological conditions.
• Provides radiotherapy solutions, including linear accelerators like Versa HD, Elekta Unity MR-Linac, and Elekta Harmony.
• Offers comprehensive treatment management, quality assurance, and motion management technologies.
• Supplies brachytherapy products, such as image-guided systems, applicators, and afterloaders.
• Manufactures the Leksell Gamma Knife series for precise radiosurgery of brain disorders.
• Provides neurosurgery products, including stereotactic systems for intracranial and minimally invasive procedures.
• Offers cloud-based managed hosting services for cancer care management.
• Headquartered in Stockholm, Sweden, with a global operational footprint.

How Does EKTAF Make Money?

• Sells advanced medical equipment, including linear accelerators, brachytherapy systems, and radiosurgery devices, to hospitals and cancer treatment centers.
• Generates revenue from software licenses and subscriptions for treatment management, planning, and quality assurance platforms (e.g., MOSAIQ Plaza).
• Provides ongoing service and maintenance contracts for its installed base of medical devices.
• Offers managed hosting services (e.g., Elekta Axis Cloud) for secure and efficient data management in oncology.
• Sells specialized consumables and applicators for brachytherapy procedures.

What Industry Does EKTAF Operate In?

Elekta AB (publ) operates in the Medical - Instruments & Supplies industry, a critical segment within the broader Healthcare sector. This industry is characterized by continuous innovation, stringent regulatory environments, and a growing global demand driven by an aging population and increasing incidence of chronic diseases, particularly cancer. Elekta's core focus on radiation therapy, radiosurgery, and brachytherapy places it directly in the advanced cancer treatment market, which is experiencing significant technological evolution towards more precise and personalized therapies. The competitive landscape includes other major medical device manufacturers specializing in oncology solutions. Elekta differentiates itself through its comprehensive portfolio, including integrated MR-Linac technology and the renowned Leksell Gamma Knife, catering to a wide spectrum of treatment needs for cancer and neurological conditions globally. The increasing global demand for cancer treatment serves as a fundamental market trend supporting Elekta's long-term positioning.

Who Are EKTAF's Key Customers?

• Hospitals and university medical centers globally.
• Dedicated cancer treatment centers and oncology clinics.
• Neurosurgery departments and specialized neurological clinics.
• Radiation therapy departments.
• Government and private healthcare providers.

How Elekta AB (publ) Is Valued

Elekta AB (publ) carries a market capitalization of $1.93B, placing it in the small-cap category. Relative to its peer group, EKTAF's quantitative score of 47/100 is below the peer average of 62/100.

Company Profile

Elekta AB (publ) operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Stockholm, SE. The company is led by CEO Jakob Just-Bomholt. EKTAF has traded publicly since 2010.

ROE -6%Key Financial Metrics

Return on equity for Elekta AB (publ) stands at -6.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.9%, showing how much profit it generates from its asset base. Its free cash flow yield is 11.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.87 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -2.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Elekta AB (publ)'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.14 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Elekta AB (publ) revenue of about $16.81B for fiscal 2026, with EPS near $3.37. The estimate reflects 14 contributing analysts.

EKTAF Financials

EKTAF Latest News

EKTAF Analyst Consensus

EKTAF MoonshotScore

What Investors Ask About Elekta AB (publ) (EKTAF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources